ObjectiveTo observe the clinical effect of levosimendan in the treatment of patients with coronary heart aisease (CHD) complicated with acute heart failure (AHF) and its influence on serum levels of myocardial injury markers. MethodsA total of 60 patients with non-myocardial infarction CHD complicated with AHF admitted to our hospital from June 2018 to July 2019 were selected as the research objects, and according to the random number method, the patients were divided into study group and control group, with 30 cases in each group. The control group was received conventional treatment, based on which the study group was additionally given levosimendan. The left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD) and high-sensitivity C-reactive protein (hs- CRP), tumor necrosis factor-α (TNF-α), cardiac troponin (cTnl), N-terminal pro-B-type natriuretic peptide (NT-ProBNP) levels before and 7 days after treatment between the two groups were compared. The occurrence of adverse reactions during the treatment of the two groups was also compared. ResultsAfter 7 days of treatment, the LVEF level of the two groups significantly increased, and the level of the study group was significantly higher than that of the control group; meanwhile, the levels of LVESD, LVEDD, hs-CRP, TNF-α, cTnl, and NT-ProBNP significantly decreased in the two groups, and the study group yielded lower levels of the above-mentioned indicator as compared with the control group, with statistically significant differences (P＜0.05). During the treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionAdditionally administration of levosimendan based on the conventional treatment can effectively improve cardiac function of patients with CHD complicated with AHF, decrease levels of serum inflammatory indicators, and alleviate myocardial injury in patients, with a preferable safety.

无